- Home
- ADPT vs OCUL Comparison
ADPT vs OCUL Comparison
Compare ADPT & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- OCUL
- Stock Information
- Founded
- ADPT 2009
- OCUL 2006
- Country
- ADPT United States
- OCUL United States
- Employees
- ADPT N/A
- OCUL N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- ADPT Health Care
- OCUL Health Care
- Exchange
- ADPT Nasdaq
- OCUL Nasdaq
- Market Cap
- ADPT 1.1B
- OCUL 957.3M
- IPO Year
- ADPT 2019
- OCUL 2014
- Fundamental
- Price
- ADPT $7.33
- OCUL $7.31
- Analyst Decision
- ADPT Strong Buy
- OCUL Strong Buy
- Analyst Count
- ADPT 5
- OCUL 10
- Target Price
- ADPT $9.40
- OCUL $16.22
- AVG Volume (30 Days)
- ADPT 2.4M
- OCUL 1.9M
- Earning Date
- ADPT 05-01-2025
- OCUL 05-06-2025
- Dividend Yield
- ADPT N/A
- OCUL N/A
- EPS Growth
- ADPT N/A
- OCUL N/A
- EPS
- ADPT N/A
- OCUL N/A
- Revenue
- ADPT $178,957,000.00
- OCUL $63,723,000.00
- Revenue This Year
- ADPT $21.20
- OCUL $13.32
- Revenue Next Year
- ADPT $22.06
- OCUL $13.13
- P/E Ratio
- ADPT N/A
- OCUL N/A
- Revenue Growth
- ADPT 5.10
- OCUL 9.03
- 52 Week Low
- ADPT $2.28
- OCUL $4.06
- 52 Week High
- ADPT $9.01
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- ADPT 43.95
- OCUL 51.39
- Support Level
- ADPT $7.38
- OCUL $6.94
- Resistance Level
- ADPT $8.30
- OCUL $7.83
- Average True Range (ATR)
- ADPT 0.75
- OCUL 0.72
- MACD
- ADPT -0.04
- OCUL 0.07
- Stochastic Oscillator
- ADPT 33.85
- OCUL 74.57
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.